Zepbound Dosing Schedule: How Titration Actually Works

The FDA-Approved Titration Schedule, Step by Step

Zepbound's label sets the starting dose at 2.5 mg, injected once a week for four weeks. This starting dose is not intended for long-term use. It exists only to begin treatment and let the body adjust.

After that first four weeks, the label allows the dose to increase in 2.5 mg steps, with at least four weeks required at each new dose before the next increase. That produces this sequence: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each step held for a minimum of four weeks.

Of these six dose levels, three are labeled as maintenance doses: 5 mg, 10 mg, and 15 mg. The 2.5 mg, 7.5 mg, and 12.5 mg levels exist only as transition steps on the way up. The label sets 15 mg as the maximum dose for any indication. Not every patient reaches 15 mg, and the label does not instruct that every patient should.

Why Titration Exists: The GI-Tolerability Reasoning

Tirzepatide belongs to a drug class, GLP-1 and GIP receptor agonists, that slows how fast the stomach empties and changes appetite signaling. Both effects are strongest right after a dose increase, which is when nausea, diarrhea, and other digestive symptoms are most likely to show up.

A slow step-up schedule gives the digestive system time to adjust at each level before the next increase. This is not unique to Zepbound. Every approved drug in the GLP-1 and GIP class uses a similar gradual titration approach, because starting directly at a high dose produces far more gastrointestinal side effects than most patients would tolerate.

The four-week minimum between increases reflects how long it generally takes for the body to adapt to a given dose level in the trials that supported approval. It is a built-in pacing rule, not a suggestion a patient can speed up or slow down without their prescriber's input.

What the SURMOUNT Trials Showed at Each Dose Tier

The SURMOUNT-1 trial, published in the New England Journal of Medicine, tested tirzepatide against a placebo in adults with obesity, or overweight with a related health condition, over 72 weeks. Researchers randomly assigned participants to one of three maintenance dose groups, 5 mg, 10 mg, or 15 mg, and tracked average body-weight change in each group.

At 72 weeks, the average body-weight reduction was 16.0 percent in the 5 mg group, 21.4 percent in the 10 mg group, and 22.5 percent in the 15 mg group, compared with 2.4 percent in the placebo group. These are group averages across hundreds of trial participants, not a prediction for any one person.

The trial also tracked how many participants hit certain weight-loss milestones. About 89 percent of the 5 mg group and 96 percent of both the 10 mg and 15 mg groups lost at least 5 percent of their starting body weight. At the 20 percent milestone, roughly 32 percent of the 5 mg group, 55 percent of the 10 mg group, and 63 percent of the 15 mg group reached that mark, against 1.3 percent in the placebo group.

Read as trial data, these numbers show that average results were larger in the higher-dose groups. That is a description of what happened to groups of trial participants over 72 weeks under close medical monitoring. It is not a statement that a higher dose is the right choice for any specific reader, and results for one person can differ substantially from a group average in either direction.

What Determines a Patient's Maintenance Dose

The label instructs prescribers to weigh treatment response and tolerability when choosing a maintenance dose, not to move every patient to the maximum dose by default. Several factors typically go into that decision.

• Tolerability at each step. If side effects are hard to manage at a given dose, the label explicitly allows staying at a lower maintenance dose instead of continuing to increase.
• Response so far. A prescriber looks at weight, appetite, and other measures at the current dose before deciding whether an increase adds meaningful benefit.
• Other health conditions. Conditions such as gallbladder disease, a history of pancreatitis, or other medications can factor into how a prescriber paces titration.
• Coverage and formulary rules. Some insurance plans limit which dose strengths they cover, which can shape what is practically available regardless of the clinical picture.

All four of these factors are things a prescriber reviews with an individual patient over time. None of them can be reduced to a single number that applies to everyone, which is why this page reports what the label and trials say without turning that into a recommendation.

Missed Doses and Staying Longer at a Lower Step

Zepbound's label includes specific instructions for a missed weekly dose. If a dose is missed, the label states it can be taken as soon as possible within 4 days, or 96 hours, of the missed time. If more than four days have passed, the label instructs skipping that dose and resuming the regular weekly schedule on the next scheduled day. Consecutive doses still need to stay at least 72 hours apart.

The label also builds in flexibility for patients who need more time to adjust to a dose. If a maintenance dose causes side effects that are hard to tolerate, the label allows a prescriber to hold at a lower maintenance dose rather than continuing the step-up schedule on a fixed timeline.

Both of these situations, a missed weekly dose and a slower titration pace, are managed between a patient and their prescriber. This page describes what the label allows; it is not a substitute for that conversation if a dose is missed or a step is not going well.

Why This Page Won't Name the "Most Effective" Dose

A common question is which Zepbound dose works best. This page will not answer that question with a recommendation, and that is a deliberate choice, not an omission.

The SURMOUNT-1 averages above show that, as a group, participants on higher maintenance doses lost more weight on average than participants on lower doses. But a group average describes what happened across hundreds of people under trial conditions. It does not predict how any single reader will respond, tolerate side effects, or weigh the tradeoffs at a given dose.

Choosing a maintenance dose means balancing trial averages against an individual's own tolerability, health history, and response over time. That balancing act is exactly what a prescriber is trained to do during regular visits, and it is the reason dosing decisions sit with a clinician rather than with a general information page.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

GE

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →